Investigating genetic causes in twins with different health outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The DISCO-TWIN study focuses on analyzing monozygotic twin pairs where one twin is healthy and the other is affected by a molecularly undiagnosed disease. Using advanced omics technologies, including next-generation sequencing (NGS), the study aims to identify genetic predispositions that may explain the health discrepancies between the twins. Data on phenotypes and genetic information will be shared within the University Hospital Tübingen and with external collaborators to enhance diagnostic accuracy for the participants. This observational study seeks to improve understanding of rare diseases and their genetic underpinnings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Twin pair monozygotic clinically (phenotypic) discordant twins
* Unclear diagnosis
* Suspected (mono-)genetic cause of the disease in one twin

Exclusion Criteria:

* Missing informed consent of both twin/ legal representative
* No distinct phenotype

Where it's running

• University Hospital Tübingen
  Tübingen, Germany Recruiting

Study contacts

• Principal investigator: Jeannette Hübener-Schmid, Dr. — University Hospital Tuebingen
• Study coordinator: Jeannette Hübener-Schmid, Dr.
• Email: jeannette.huebener@med.uni-tuebingen.de
• Phone: +49 7071 29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genome-based management for patients with unclear genetic diseases

  This study is testing if using whole genome sequencing as a first step can help find the causes of unclear genetic diseases in about 12,000 patients.

  Recruiting University Hospital Tuebingen · Tübingen · NCT04760522

• Sirolimus for ApoE4 Carriers: Testing Brain Blood Flow in Women 45-65

  Researchers will test whether sirolimus can improve brain blood flow in healthy ApoE4-positive women ages 45 to 65 compared with a placebo.

  Recruiting Phase 1 University of Missouri-Columbia · Columbia, Missouri · NCT07728175

• AI-assisted Rare-Disease Diagnosis

  A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.

  Recruiting at 3 sites Peking Union Medical College Hospital · Cangzhou and 11 other locations · NCT07650799

• Socio‑professional inclusion for young people (15–25) with childhood-onset rare genetic disabilities

  This project will try to see what makes it hard for 15–25‑year‑olds with childhood-onset rare genetic conditions to access higher education, internships, or work.

  Recruiting Imagine Institute · Paris, Île-de-France Region · NCT07527624

• Treatment approaches for AChR-antibody positive generalized myasthenia gravis in Russia.

  This project will look at which treatments adults in Russia with AChR-antibody positive generalized myasthenia gravis receive and how their symptoms and hospitalizations change over time.

  Recruiting at 7 sites AstraZeneca · Kazan' and 6 other locations · NCT07247279

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.